LAUSR

The present study investigated the relationship between MLH1, MSH2, MSH3, and MSH6 polymorphisms and toxicity due to platinum‐based doublet chemotherapy for North Indian lung cancer patients. Polymerase chain reaction‐restriction fragment length polymorphism technique was used to assess the polymorphism. For MSH2 IVS1 + 9G > C polymorphism variant type genotype reported a 1.4‐fold increased risk of anemia (AOR = 1.4; 95% CI = 0.98–1.99; p = 0.04) and decreased risk of developing gastrointestinal toxicity (diarrhea) (AOR = 0.53; 95% CI = 0.28–1.01; p = 0.04). Further, we also reported a 10‐fold increased risk of developing severe grade anorexia in combined genotype (GC + CC) (AOR = 9.18; 95% CI = 0.98–86.1; p = 0.05). For MSH2 T > C/‐6 polymorphism, variant type reported a 3‐fold and 2‐fold increased risk of developing severe grade leukopenia (AOR = 3.37; 95% CI = 1.44–7.88; p = 0.005) and neutropenia respectively (AOR = 2.23; 95% CI = 1.07–4.66; p = 0.03). For MSH3 G > A polymorphism, heterozygous (GA) and combined genotype (GA + AA) reported a 7‐fold and 6‐fold increased risk of developing anemia (AOR = 7.23; 95% CI = 1.51–34.6; p = 0.01, AOR = 6.39; 95% CI = 1.53–26.6; p = 0.01). Our results suggest that polymorphisms in DNA mismatch repair genes are associated with hematological, and gastrointestinal toxicities and might be considered a predictor for pretreatment evaluation in lung cancer patients.